1. Home
  2. NVT vs INSM Comparison

NVT vs INSM Comparison

Compare NVT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nVent Electric plc

NVT

nVent Electric plc

HOLD

Current Price

$168.37

Market Cap

28.6B

Sector

Industrials

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$102.15

Market Cap

23.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVT
INSM
Founded
1903
1988
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6B
23.0B
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
NVT
INSM
Price
$168.37
$102.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
24
Target Price
$131.36
$201.17
AVG Volume (30 Days)
1.9M
4.4M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
0.61%
N/A
EPS Growth
118.78
N/A
EPS
0.87
N/A
Revenue
$3,893,100,000.00
N/A
Revenue This Year
$19.44
$182.31
Revenue Next Year
$12.41
$65.19
P/E Ratio
$211.89
N/A
Revenue Growth
29.51
N/A
52 Week Low
$69.04
$90.39
52 Week High
$184.64
$212.75

Technical Indicators

Market Signals
Indicator
NVT
INSM
Relative Strength Index (RSI) 51.76 45.73
Support Level $152.61 $98.90
Resistance Level $176.50 $166.81
Average True Range (ATR) 7.51 5.41
MACD 0.17 1.39
Stochastic Oscillator 49.34 72.79

Price Performance

Historical Comparison
NVT
INSM

About NVT nVent Electric plc

NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: